GeoVax Labs (GOVX) Competitors $2.29 -0.03 (-1.29%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GOVX vs. KPTI, ANL, QNCX, TNXP, PMVP, ALXO, GNLX, IKNA, CLSD, and ENTXShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Karyopharm Therapeutics (KPTI), Adlai Nortye (ANL), Quince Therapeutics (QNCX), Tonix Pharmaceuticals (TNXP), PMV Pharmaceuticals (PMVP), ALX Oncology (ALXO), Genelux (GNLX), Ikena Oncology (IKNA), Clearside Biomedical (CLSD), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Karyopharm Therapeutics Adlai Nortye Quince Therapeutics Tonix Pharmaceuticals PMV Pharmaceuticals ALX Oncology Genelux Ikena Oncology Clearside Biomedical Entera Bio GeoVax Labs (NASDAQ:GOVX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations. Does the MarketBeat Community favor GOVX or KPTI? Karyopharm Therapeutics received 513 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 95.65% of users gave GeoVax Labs an outperform vote while only 72.20% of users gave Karyopharm Therapeutics an outperform vote. CompanyUnderperformOutperformGeoVax LabsOutperform Votes2295.65% Underperform Votes14.35%Karyopharm TherapeuticsOutperform Votes53572.20% Underperform Votes20627.80% Is GOVX or KPTI more profitable? GeoVax Labs has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -58.93%. Karyopharm Therapeutics' return on equity of 0.00% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax LabsN/A -809.87% -349.34% Karyopharm Therapeutics -58.93%N/A -41.25% Do analysts prefer GOVX or KPTI? GeoVax Labs presently has a consensus target price of $14.20, suggesting a potential upside of 520.09%. Karyopharm Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 687.40%. Given Karyopharm Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than GeoVax Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in GOVX or KPTI? 6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by company insiders. Comparatively, 4.3% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer GOVX or KPTI? In the previous week, GeoVax Labs had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Karyopharm Therapeutics. GeoVax Labs' average media sentiment score of 0.44 beat Karyopharm Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media. Company Overall Sentiment GeoVax Labs Neutral Karyopharm Therapeutics Neutral Which has better valuation & earnings, GOVX or KPTI? GeoVax Labs has higher earnings, but lower revenue than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$3.09M6.99-$25.97MN/AN/AKaryopharm Therapeutics$148.44M0.54-$143.10M-$1.14-0.56 Which has more volatility & risk, GOVX or KPTI? GeoVax Labs has a beta of 3.24, indicating that its stock price is 224% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. SummaryGeoVax Labs beats Karyopharm Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.61M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.88%4.21%P/E RatioN/A10.5090.8317.14Price / Sales6.99195.361,112.01116.85Price / CashN/A57.1642.0237.88Price / Book0.715.104.774.78Net Income-$25.97M$151.51M$119.70M$225.60M7 Day Performance-2.55%-2.11%-1.86%-1.23%1 Month Performance-15.19%-3.11%11.45%3.07%1 Year Performance-55.88%11.53%30.43%16.48% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs2.9348 of 5 stars$2.29-1.3%$14.20+520.1%-54.8%$21.61M$3.09M0.0017Analyst ForecastNews CoverageKPTIKaryopharm Therapeutics3.8062 of 5 stars$0.69-1.3%$5.00+623.5%-16.2%$87.21M$148.44M-0.61380ANLAdlai Nortye1.5882 of 5 stars$2.36+3.1%$9.00+281.4%-75.7%$87.08M$5M0.00127QNCXQuince Therapeutics3.0834 of 5 stars$1.90-6.4%$8.50+347.4%+60.4%$83.60MN/A-1.6460Analyst ForecastAnalyst RevisionNews CoverageTNXPTonix Pharmaceuticals3.6123 of 5 stars$0.44+83.8%$53.50+12,001.3%-95.0%$82.63M$11.29M0.00103High Trading VolumePMVPPMV Pharmaceuticals1.7962 of 5 stars$1.58flat$5.80+267.1%-34.5%$81.77MN/A0.0050Positive NewsALXOALX Oncology3.191 of 5 stars$1.55+6.6%$10.67+590.4%-87.7%$81.49MN/A-0.4940Analyst ForecastNews CoverageGNLXGenelux0.8851 of 5 stars$2.32-0.4%$18.25+686.6%-82.9%$80.13M$8,000.00-2.4510IKNAIkena Oncology2.8796 of 5 stars$1.64-0.6%$3.00+82.9%-20.5%$79.14M$659,000.00-1.3470CLSDClearside Biomedical2.9023 of 5 stars$1.04+2.0%$5.33+412.8%-12.8%$78.87M$8.23M-2.2930News CoverageENTXEntera Bio1.4405 of 5 stars$2.20+1.9%$10.00+354.5%+195.8%$78.72M$130,000.00-8.3120 Related Companies and Tools Related Companies KPTI Competitors ANL Competitors QNCX Competitors TNXP Competitors PMVP Competitors ALXO Competitors GNLX Competitors IKNA Competitors CLSD Competitors ENTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GOVX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GOVX Stock Alerts